In a report published Monday, Stifel analyst Brian Klein terminated coverage on
Oncolytics Biotech (NASDAQ:
ONCY).
In the report, Stifel noted, "Due to a reallocation of resources, we are discontinuing coverage of Oncolytics Biotech Inc. (ONCY). Our most recent rating of Hold should no longer be used as an indicator for the company going forward."
Oncolytics Biotech closed on Friday at $0.42.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
